Navigation Links
Shamir Optical Industry Ltd. Announces Declaration of a Cash Dividend
Date:1/14/2008

KIBBUTZ SHAMIR, Israel, Jan. 14 /PRNewswire-FirstCall/ -- Shamir Optical Industry Ltd. (Nasdaq: SHMR) ("Shamir"), a leading provider of innovative products and technology to the progressive ophthalmic lens market, announced today that its board of directors had declared a dividend distribution in an aggregate amount of US$ 4.0 million (approximately NIS 15.1 million based on the January 11, 2008 representative rate of exchange), or approximately US$ 0.243 (approximately NIS 0.917 based on the January 11, 2008 representative rate of exchange) per ordinary share based on the number of outstanding shares of Shamir as of the date hereof.

The dividend will be payable on or about February 25, 2008, to shareholders of record as of the close of business on February 11, 2008.

The dividend will be paid to Shamir shareholders in US Dollars, except for holders of Shamir shares traded on Tel-Aviv Stock Exchange (i.e., shares registered in the name of the nominee company of Bank Hapoalim Ltd.), who will be paid in NIS according to the representative rate of exchange published by the Bank of Israel on February 22, 2008.

The dividend will be paid to the Shamir shareholders net of taxes to be withheld at source pursuant to Israeli law. The maximum weighted withholding tax rate is 15.07%.

About Shamir

Shamir is a leading provider of innovative products and technology to the progressive spectacle lens market. Utilizing its proprietary technology, the company develops, designs, manufactures, and markets progressive lenses to sell to the ophthalmic market. In addition, Shamir utilizes its technology to provide design services to optical lens manufacturers under service and royalty agreements. Progressive lenses are used to t
'/>"/>

SOURCE Shamir Optical Industry Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Shamir Optical Industry Ltd. Reports Third Quarter 2007 Results
2. Nanofabrication method paves way for new optical devices
3. New Optical Breast Cancer Imaging Technology Garners Cover Story in National Radiology Magazine
4. CRi Announces Maestro 2, the Next Generation in Vivo Optical Imaging Systems
5. Ultrafast optical shutter is switched entirely by laser light
6. Ohio Ranks Best in the Midwest for Venture Capital Investment in Health Care Bioscience Industry
7. Advanced Cell Technologys Dr. Robert Lanza Makes List of 100 Most Inspiring People in the Life-Sciences Industry
8. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
9. Favrille CEO to Present at NewsMakers in the Biotech Industry Investment Conference
10. NeurogesX to Present at BioCenturys NewsMakers in the Biotech Industry Conference
11. DURECT Corporation to Present at the NewsMakers in the Biotech Industry Investment Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... MA (PRWEB) , ... August 27, 2015 , ... Inc. ... United States, ranking iLab Solutions as number 1,361 in growth for the three years ... of the top 0.1% fastest-growing privately held organizations in the country. , “We ...
(Date:8/27/2015)... ... August 27, 2015 , ... Proove ... new data on the relationship of genetics and hypertension at the International ... Disease in Vancouver, British Columbia, Canada. The event, which boasts an extensive overview ...
(Date:8/26/2015)... , Aug. 26, 2015  Roka Bioscience, Inc. (NASDAQ: ... providing advanced testing solutions for the detection of foodborne ... present at the Sidoti & Company Emerging Growth Conference ... be held at the New York Marriott Marquis. ... be available through the investor relations section of Roka ...
(Date:8/26/2015)... , Aug. 26, 2015  Platform therapeutic ... it has received a $1.5M Phase II SBIR ... to further develop its therapeutic agent to reduce ... need in end stage renal disease (ESRD) patients ... National Institute of Diabetes and Digestive and Kidney ...
Breaking Biology Technology:iLab Solutions Named to 2015 Inc. 5000 List 2iLab Solutions Named to 2015 Inc. 5000 List 3Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 2Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 3Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 2Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 3
... SUNNYVALE, Calif., June 1 Pharmacyclics, Inc. (Nasdaq: ... on Form S-3 with the Securities and Exchange Commission (the ... The rights offering will be made through the distribution of ... stock, par value $0.0001 per share, at a subscription price ...
... ... Generation nonfood Biofuel crops Knowledge Platform ,CJP,s "3rd Global Jatropha Hi-Tech ... all set to provide the most authoritative Knowledge platform for Development ... Priorities to Feed Biodiesel Industry Worldwide. The biodiesel industry has met ...
... and VANCOUVER, May 30 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. ... of a Phase 1 trial presented during an oral ... Annual Meeting. Preliminary results as of April 2009 showed ... addition, OGX-427 demonstrated declines in circulating tumor cells at ...
Cached Biology Technology:Pharmacyclics Files Registration Statement for Rights Offering 2Pharmacyclics Files Registration Statement for Rights Offering 3Pharmacyclics Files Registration Statement for Rights Offering 4Jatrophaworld Training 2009: 2nd Generation nonfood Biofuel crops Knowledge Platform 2Jatrophaworld Training 2009: 2nd Generation nonfood Biofuel crops Knowledge Platform 3Jatrophaworld Training 2009: 2nd Generation nonfood Biofuel crops Knowledge Platform 4OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial 2OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial 3OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial 4OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial 5
(Date:7/31/2015)... China , 31 de julho de 2015 /PRNewswire/ ... (ICG-10, www.icg-10.org ) será realizada pela BGI de 22-25 ... . A conferência está celebrando seu ... em 2006, a ICG se tornou uma das reuniões ... um dos encontros científicos mais dinâmicos, entusiastas e prazerosos. ...
(Date:7/31/2015)... China , 31 de julio de 2015 ... www.icg-10.org ) se celebrará por medio de BGI del 22 al ... . Este año, la conferencia celebra ... ICG se ha convertido en una de las reuniones anuales ... ser una de las reuniones más dinámicas, entusiastas y mejores ...
(Date:7/31/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... growing mobile commerce market and creator of the Wocket® ... 62/198989 for ELECTRONIC CRYPTO-CURRENCY MANAGEMENT METHOD AND ... advance crypto-currencies such as Bitcoin into the consumer market ... to manage all payments.  The technology ...
Breaking Biology News(10 mins):A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 3La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 2La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 3NXT-ID Patents Electronic Crypto-Currency Management Technology 2NXT-ID Patents Electronic Crypto-Currency Management Technology 3NXT-ID Patents Electronic Crypto-Currency Management Technology 4
... ago that many genes likely influence how tall a person ... the myriad genes. Now an international research team brings light ... with human height the first consistent genetic link to ... advance online edition of Nature Genetics, stem from a large-scale ...
... Mass. -- Biologists at Harvard University have identified the ancient ... of orchids in the fossil record, a find they say ... Their analysis, published this week in the journal Nature, ... much longer ago than many scientists had estimated. The extinct ...
... (August 30, 2007) Saudi Arabias King Abdullah University ... Institute of Technology, Bombay (IIT Bombay) , signed ... to work together to foster world-class programs that will ... fundamental and applied chemical sciences for the benefit of ...
Cached Biology News:Genome study shines light on genetic link to height 2Genome study shines light on genetic link to height 3First orchid fossil puts showy blooms at some 80 million years old 2First orchid fossil puts showy blooms at some 80 million years old 3Saudi Arabia's KAUST and IIT, Bombay to Collaborate on Scientific Research 2
Rabbit polyclonal to NCoR2, prediluted ( Abpromise for all tested applications). entrezGeneID: 9612 SwissProtID: Q9Y618...
...
... clone 41D GenBank Accession Number ... clusterin purified from human serum Formulation: ... and 0.05% sodium azide Quality Assurance: ... HeLa cells or MCF-7 cell lysates. ...
Anti-CoralHue Dronpa Green Monoclonal Antibody Research Focus: cell surface antigens Storage: -20C Shipping Temperature: +4C...
Biology Products: